Last Updated on December 22, 2024 by The Health Master
Form 483
Cipla Limited‘s US-based subsidiary, InvaGen Pharmaceuticals, recently underwent scrutiny by the United States Food and Drug Administration (USFDA), resulting in the issuance of Form 483 with five inspectional observations.
This development comes after an inspection conducted at InvaGen’s manufacturing facility in Central Islip, Long Island, New York, USA, spanning from September 11th to September 19th, 2023.
Inspection details on Form 483:
During the inspection period, InvaGen Pharmaceuticals received five inspectional observations, as detailed in Form 483, a standard document utilized by the USFDA to highlight deficiencies in quality systems or regulatory compliance.
Specifics of the Observations:
Cipla clarified that none of the observations were related to repeat infractions or data integrity concerns, offering assurance of their commitment to promptly address the identified issues in collaboration with the USFDA within the designated timeframe.
Understanding Form 483:
Form 483 serves as an official notice from the USFDA, indicating areas where a manufacturer may be falling short in terms of quality control or regulatory adherence.
It acts as a crucial feedback mechanism, prompting companies to rectify these concerns in order to maintain compliance with industry standards.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
USFDA issues Form 483 with one observation to Aurobindo
USFDA issues Form 483 with 2 observations to Gland Pharma: Hyderabad
USFDA issued EIR to Torrent Pharma: Gujarat
Procedural lapses flagged at Aurobindo Pharma by USFDA: Telangana
USFDA completes PADE inspection at Marksans with 2 observations
USFDA concludes inspection at Granules Pharma with zero observations
Phase I Clinical Trial permission Granted for Chickenpox Vaccine
USFDA declines to approve Nasal Spray for allergic reactions
Boost for Medical Device Testing: CDSCO approves Nine New Laboratories
CDSCO and Jharkhand Govt host 3-Day Training program for Drug Regulators
Drug alert: 48 out of 1166 samples declared as NSQ in August 2023
Revised Schedule M: CDSCO organizes nationwide Workshops
Govt’s bold moves to boost Pharma Industry and others
Regulators investigate Medical Device Company for Potential Antitrust Violations
NPPA extends ceiling Price Fixation for Orthopaedic Knee Implants
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
